Answers are grounded in this paper and cite their sources.
Shows that macrophage deficiency of SNX25 reduces plaque formation in mice, suggesting potential therapeutic targets.
SNX25 is a member of the sorting nexin (SNX) superfamily, which plays crucial roles in membrane trafficking, cell signaling, and organelle dynamics. Our research has focused extensively on SNX25, demonstrating that SNX25-positive macrophages participate in inflammatory responses and pain perception through various signaling pathways. Atherosclerosis is now widely recognized as a chronic inflammatory disease of the vasculature, with macrophages serving as central contributors to its progression. These macrophages accumulate after internalizing oxidized low-density lipoproteins (oxLDL), transforming into foam cells that elicit inflammatory responses and promote atherosclerotic progression. To explore the impact of SNX25 on atherosclerosis, we induced the condition in apolipoprotein E-deficient (APOE−/−) mice using a high-fat diet. As expected, SNX25 expression was observed in macrophages within atherosclerotic plaques. In SNX25+/− mice on an APOE−/− genetic background, plaque size was significantly smaller than in their SNX25+/+ counterparts. Furthermore, bone marrow transplantation from SNX25+/− mice into APOE−/− recipients resulted in a marked reduction in foam cell formation and accumulation compared to transplants from SNX25+/+ donors. These histopathological findings suggest that SNX25 may regulate macrophage activity under pathological conditions, identifying a novel role for SNX25 in the pathogenesis of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Isonishi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: